%0 Journal Article %A Emanuele Pepe %A Paolo Bajardi %A Laetitia Gauvin %A Filippo Privitera %A Brennan Lake %A Ciro Cattuto %A Michele Tizzoni %T COVID-19 outbreak response: a first assessment of mobility changes in Italy following national lockdown %D 2020 %R 10.1101/2020.03.22.20039933 %J medRxiv %P 2020.03.22.20039933 %X Italy is currently experiencing the largest COVID-19 outbreak in Europe so far, with more than 45,000 confirmed cases. Following the identification of the first infections, on February 21, 2020, national authorities have put in place an increasing number of restrictions aimed at containing the outbreak and delaying the epidemic peak. Since March 9, the whole country is under lockdown. Here we provide the first quantitative assessment of the impact of such measures on the mobility and the social mixing of Italians, through the analysis of a large-scale dataset on de-identified, geo-located smartphone users. With respect to pre-outbreak averages, we estimate a reduction of 50% of the total trips between Italian provinces, following the lockdown. In the same week, the average users’ radius of gyration has declined by about 50% and the average degree of the users’ proximity network has dropped by 17% at national level.Competing Interest StatementMT reports consulting fees from GlaxoSmithKline plc, outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work.Funding StatementEP, LG, CC, MT gratefully acknowledge the support of the Lagrange Project funded by CRT Foundation. PB acknowledges support from Intesa Sanpaolo Innovation Center. This work was partially funded by the Epipose project from the European Union’s SC1-PHE-CORONAVIRUS-2020 programme, project number 101003688. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw geo-located data analyzed in the study are not publicly available due to privacy reasons. All the data underlying the figures are deposited in the Humanitarian Data Exchange COVID-19 Outbreak page: https://data.humdata.org/event/covid-19 %U https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.22.20039933.full.pdf